Article Sidebar

pdf
Date Published: 09/07/2024
Online Published: 31/12/2023
Abstract Views: 47
Views pdf: 21
DOI: https://doi.org/10.55046/vjrnm.53.1035.2023
Issue
No. 53 (2023)
Section
Scientific research
How to Cite
Nguyễn, T. H., Ngo, L. L., Pham , M. T., & Nguyen , D. A. (2023). TITLE: INITIAL ASSESSMENT OF EARLY RESPONSE TO HEPATIC ARTERIAL INFUSION CHEMOTHERAPY USING LIPIODOL, CISPLATIN, AND 5-FU FOR LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA. Vietnamese Journal of Radiology and Nuclear Medicine, 53, 15-22. https://doi.org/10.55046/vjrnm.53.1035.2023

TITLE: INITIAL ASSESSMENT OF EARLY RESPONSE TO HEPATIC ARTERIAL INFUSION CHEMOTHERAPY USING LIPIODOL, CISPLATIN, AND 5-FU FOR LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA

Thị Hiểu Nguyễn1, Ngo Le Lam2,, Professor Pham Minh Thong3, Nguyen Duy Anh2
1 Bệnh viện K
2 Center for Diagnostic Imaging, K Central Hospital
3 Department of Imaging Diagnosis, Hanoi Medical University

Main Article Content

Abstract

Purpose: This study aimed to evaluate the early response (ER) in patients who had locally advanced hepatocellular carcinoma (HCC) treated with hepatic arterial infusion chemotherapy (HAIC) of Lipiodol, Cisplatin, and 5-FU.


Materials and methods: We conducted a prospective study involving ten locally advanced HCC patients, each received an implanted subcutaneous port for HAIC. The treatment regimen consisted of Lipiodol, Cisplatin, and 5-FU. One week after the first course, the patients were examined, performed CT-scanner and categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) using mRECIST criteria.


Results: 6 patients (60%) patients had ER after treatment, with one of thesse (1%) achieving CR and five (50%) with PR. One patient (10%) exhibited PD, while two (20%) demonstrated SD. Mean viable tumor portion size decreased from 102±41mm to 83±53mm, statistics significance with p <0.05. Furthermore, the portal vein tumor thrombosis shrunk in  2 patients (20%), and liver function  improved in 2 patients (20%). Mean tumour diameter Complications occurred in three patients (30%), including infection, hematoma, thrombosed catheter, and catheter breakage.


Conclusions: The HAIC regimen consisting of Lipiodol, Cisplatin, and 5-FU achieved a high rate of early response (ER), the shrinkage of portal vein tumor thrombosis, and improved liver function.

Article Details

Keywords

HAIC, UTBMTBG, HKTMC.

References

1. Sung H., Ferlay J., Siegel R.L., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
2. Nguyen-Dinh S.-H., Do A., Pham T.N.D., et al. (2018). High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. WJH, 10(1), 116–123.
3. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | American Society of Clinical Oncology Educational Book. , accessed: 11/12/2023.
4. Reig M., Forner A., Rimola J., et al. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 76(3), 681–693.
5. Sun J.-X., Shi J., Li N., et al. (2016). Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biology & Medicine, 13(4), 452.
6. Iwamoto H., Niizeki T., Nagamatsu H., et al. (2022). The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function. Cancers (Basel), 14(19), 4873.
7. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1) - PubMed. , accessed: 10/27/2023.
8. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update - FullText - Liver Cancer 2021, Vol. 10, No. 3 - Karger Publishers. , accessed: 10/21/2022.
9. Ikeda M., Shimizu S., Sato T., et al. (2016). Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol, 27(11), 2090–2096.
10. Chuma M., Uojima H., Hiraoka A., et al. (2021). Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatol Res, 51(2), 201–215.
11. Tao Z.-W., Cheng B.-Q., Zhou T., et al. (2022). Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary & Pancreatic Diseases International, 21(2), 134–144.
12. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update - FullText - Liver Cancer 2021, Vol. 10, No. 3 - Karger Publishers. , accessed: 03/06/2023.
13. Lin C.-C., Hung C.-F., Chen W.-T., et al. (2015). Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer, 4(4), 228–240.
14. Niizeki T., Iwamoto H., Shirono T., et al. (2021). Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers, 13(17), 4450.
15. Barnett K.T. and Malafa M.P. (2001). Complications of Hepatic Artery Infusion : A Review of 4580 Reported Cases. IJGC, 30(3), 147–160.
16. Ogasawara S., Kanogawa N., and Kato N. (2022). How we use hepatic arterial infusion chemotherapy in the new era of systemic therapy?. Hepatobiliary Surg Nutr, 11(5), 775–778.